End-of-day quote
Other stock markets
|
||
- | - |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
May. 01 | HSS Hire annual profit falls amid investment spending; CFO to depart | AN |
Sales 2024 * | 347M 441M 0 | Sales 2025 * | 360M 457M 0 | Capitalization | 67.26M 85.34M 0 |
---|---|---|---|---|---|
Net income 2024 * | 6M 7.61M - | Net income 2025 * | 7M 8.88M - | EV / Sales 2024 * | 0.47 x |
Net Debt 2024 * | 95.22M 121M 0 | Net Debt 2025 * | 99.75M 127M 0 | EV / Sales 2025 * | 0.46 x |
P/E ratio 2024 * |
10.8
x | P/E ratio 2025 * |
9.55
x | Employees | - |
Yield 2024 * |
6.05% | Yield 2025 * |
6.23% | Free-Float | 24.68% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Ashmore
CEO | Chief Executive Officer | 60 | 17-05-31 |
Paul Quested
DFI | Director of Finance/CFO | 54 | 16-04-30 |
Daniel Joll
BRD | Director/Board Member | - | 15-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 15-01-08 | |
Director/Board Member | 71 | 15-01-08 | |
Alan Peterson
CHM | Chairman | 77 | 12-11-30 |
1st Jan change | Capi. | |
---|---|---|
+24.23% | 46.24B | |
+11.42% | 32.74B | |
+24.91% | 17.59B | |
-10.11% | 7.53B | |
+19.62% | 5.5B | |
+6.96% | 4.43B | |
-3.22% | 3.71B | |
-8.99% | 2.68B | |
+18.69% | 2.2B |